These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3297320)

  • 1. Cognitive improvement in clinical trials with nootropic drugs: when can it be expected and how to clarify its meaning.
    Gainotti G; Benedetti N; Caltagirone C; Nocentini U
    Clin Neuropharmacol; 1986; 9 Suppl 3():S65-9. PubMed ID: 3297320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of oxiracetam therapy in the treatment of cognitive deficiencies secondary to primary degenerative dementia.
    Rozzini R; Zanetti O; Bianchetti A
    Acta Neurol (Napoli); 1992 Apr; 14(2):117-26. PubMed ID: 1414555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical and neurophysiological trial on nootropic drugs in patients with mental decline.
    Gallai V; Mazzotta G; Del Gatto F; Montesi S; Mazzetti A; Dominici P; Della Monica A
    Acta Neurol (Napoli); 1991 Feb; 13(1):1-12. PubMed ID: 1867125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cognitive impairment secondary to degenerative dementia. Effectiveness of oxiracetam therapy.
    Rozzini R; Zanetti O; Bianchetti A
    Acta Neurol (Napoli); 1993 Feb; 15(1):44-52. PubMed ID: 8456595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity.
    Nuechterlein KH; Green MF; Kern RS; Baade LE; Barch DM; Cohen JD; Essock S; Fenton WS; Frese FJ; Gold JM; Goldberg T; Heaton RK; Keefe RS; Kraemer H; Mesholam-Gately R; Seidman LJ; Stover E; Weinberger DR; Young AS; Zalcman S; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):203-13. PubMed ID: 18172019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can the pattern of neuropsychological improvement obtained with cholinergic drugs be used to infer a cholinergic mechanism in other nootropic drugs?
    Gainotti G; Nocentini U; Sena E
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13 Suppl():S47-59. PubMed ID: 2694229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional co-primary measures for clinical trials in schizophrenia: results from the MATRICS Psychometric and Standardization Study.
    Green MF; Nuechterlein KH; Kern RS; Baade LE; Fenton WS; Gold JM; Keefe RS; Mesholam-Gately R; Seidman LJ; Stover E; Marder SR
    Am J Psychiatry; 2008 Feb; 165(2):221-8. PubMed ID: 18172017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical trials in children with Down syndrome: issues from a cognitive research perspective.
    Heller JH; Spiridigliozzi GA; Crissman BG; Sullivan-Saarela JA; Li JS; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2006 Aug; 142C(3):187-95. PubMed ID: 16838317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nootropic effect of BR-16A (Mentat), a psychotropic herbal formulation, on cognitive deficits induced by prenatal undernutrition, postnatal environmental impoverishment and hypoxia in rats.
    Bhattacharya SK
    Indian J Exp Biol; 1994 Jan; 32(1):31-6. PubMed ID: 8045602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical factors that may confound the assessment of drug efficacy.
    Csernansky JG; Newcomer JW; Miller LS; Faustman WO
    Psychopharmacol Bull; 1991; 27(3):231-5. PubMed ID: 1775593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Challenging pharmacotherapy in dementia].
    Ihl R
    MMW Fortschr Med; 2009 Mar; 151(13):46-8. PubMed ID: 19504818
    [No Abstract]   [Full Text] [Related]  

  • 12. [The psychotropic effect of the Pyrovalerone (F-1983), placebo, the milieu therapy and mental condition of the patients in forensic psychiatry].
    Söderholm S; Viukari NM; Rimón R
    Nervenarzt; 1976 Feb; 47(2):88-93. PubMed ID: 768789
    [No Abstract]   [Full Text] [Related]  

  • 13. Medicine. What are the right targets for psychopharmacology?
    Hyman SE; Fenton WS
    Science; 2003 Jan; 299(5605):350-1. PubMed ID: 12532001
    [No Abstract]   [Full Text] [Related]  

  • 14. Oxiracetam in the treatment of multi-infarct dementia and primary degenerative dementia.
    Dysken MW; Katz R; Stallone F; Kuskowski M
    J Neuropsychiatry Clin Neurosci; 1989; 1(3):249-52. PubMed ID: 2521069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical trials of drugs. Special features of clinical studies of analgesics and psychotropic drugs].
    Hennemann A
    Med Monatsschr Pharm; 2003 Jul; 26(7):224-6. PubMed ID: 12879619
    [No Abstract]   [Full Text] [Related]  

  • 16. Activity of oxiracetam in patients with organic brain syndrome: a neuropsychological study.
    Moglia A; Sinforiani E; Zandrini C; Gualtieri S; Corsico R; Arrigo A
    Clin Neuropharmacol; 1986; 9 Suppl 3():S73-8. PubMed ID: 3594459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Animal models of cognitive function.
    Decker MW
    Crit Rev Neurobiol; 1995; 9(4):321-43. PubMed ID: 8829849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in medication clinical trials.
    Rudorfer MV
    Psychopharmacol Bull; 1993; 29(1):35-44. PubMed ID: 8378510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Some problems in the conduct of psychotropic drug trials (a review).
    Doongaji DR; Parikh MD
    J Postgrad Med; 1983 Apr; 29(2):67-74. PubMed ID: 6631765
    [No Abstract]   [Full Text] [Related]  

  • 20. Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria.
    Green MF; Nuechterlein KH; Gold JM; Barch DM; Cohen J; Essock S; Fenton WS; Frese F; Goldberg TE; Heaton RK; Keefe RS; Kern RS; Kraemer H; Stover E; Weinberger DR; Zalcman S; Marder SR
    Biol Psychiatry; 2004 Sep; 56(5):301-7. PubMed ID: 15336511
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.